Clinical trial results found that a new antibiotic candidate could shorten TB treatment from the standard 6 months to 8 weeks ...

An international team of investigators today announced promising data from a trial of a novel antibiotic that could ...

New clinical trial results presented by TB Alliance at the Union World Conference on Lung Health show that the novel ...

A new TB drug, sorfequiline, shows promising results in a multinational trial, raising hopes for faster and simpler treatment ...

In a recent study published in the Journal of Infection, researchers performed a systematic literature review of global treatment outcomes of extensively drug-resistant Tuberculosis. The study found ...

Tuberculosis (TB) is a serious infectious disease caused by the bacterium Mycobacterium tuberculosis. While multidrug treatment regimens are the standard of care, the lengthy treatment schedule and ...

Orphan designation is granted to drug candidates addressing life-threatening or chronically debilitating diseases affecting fewer than 5 in 10’000 EU residents EMA orphan status provides key ...

The global tuberculosis drugs market is anticipated to witness massive growth during the forecast period (2021 to 2031). Tuberculosis is a chronic illness that has become a global health concern.

Researchers in Boston are working to determine if an old tuberculosis vaccine could be the key to treating type 1 diabetes.